Sector: Pharmaceuticals & Biotechnology - Healthcare
BSE Code: 524322
NSE Symbol: KABRADG
ISIN: INE323K01017
📈 Kabra Drugs Appoints Ms. Monam Kapoor as Independent Director - Appointment effective April 21, 2026, subject to shareholders' approval - Term: 5 years from appointment date - Background: BCA graduate, Authorised Representative at Techtone (HK) Energy Company since July 15, 2021 - Holds DIN 092…
📈 Kabra Drugs Ltd Appoints Independent Director & Diversifies Business - Appointment of Ms. Monam Kapoor (DIN: 09278005) as Non-Executive Independent Director for a five-year term from April 21, 2026, to April 20, 2031. - Diversification of business approved, including drones & defence equipment,…
Kabra Drugs Ltd. Plans Major Business Diversification 🚀 • Board meeting scheduled for April 21, 2026, at the Corporate Office in Chennai. • Proposal to appoint Ms. Monam Kapoor (DIN: 09278005) as Additional Non-Executive Independent Director. • Discussion on diversifying business by amending the …
🔁 Kabra Drugs Ltd. Rebrands to Aanjaay Industries & Enters Defence Tech via Indonesia JV - Company name changed from Kabra Drugs Limited to Aanjaay Industries Limited, approved by Ministry of Corporate Affairs - Strategic joint venture signed with PT. Bhinneka Dwi Persada Indonesia for expansion …
Kabra Drugs Ltd Plans Expansion into Indonesia and Canada 🌍📊 - Strategic business expansion into Indonesia and Canada - Proposal to change the company name, subject to shareholder and MCA approval
📊 Kabra Drugs Ltd: No Share Issuance in Q3 FY2026 • Kabra Drugs Limited confirms SEBI Regulation 32 does not apply for the quarter ended December 31, 2025. • The company did not issue any shares through public, rights, or preferential issues during this quarter. • No statements on deviations in f…
📈 Kabra Drugs Q3 FY26: Revenue Jumps to ₹3,042 Lakhs, Returns to Profit • Q3 FY26 revenue from operations: ₹3,042 lakhs • Nine months total income (ended Dec 31, 2025): ₹5,771.32 lakhs • Q3 FY26 net profit: ₹256.65 lakhs vs losses in Q1 FY25 (₹49.98 lakhs loss) and Q3 FY24 (₹53.69 lakhs loss) • N…
Kabra Drugs Ltd Q3 FY26: Net Profit of ₹256.65 Lakhs 📊 • Revenue from operations for Q3 FY26: ₹3,042.00 lakhs • Total income for Q3 FY26: ₹3,060.43 lakhs • Net profit after tax for Q3 FY26: ₹256.65 lakhs (vs. loss of ₹53.69 lakhs in same quarter last year) • Nine-month net profit after tax: ₹390.…
📅 Kabra Drugs Ltd Q3 FY26 Results: Board Meeting Set for Feb 13 - Board meeting scheduled for Friday, 13th February 2026 at 5 PM at the corporate office in Chennai - Agenda includes consideration and approval of unaudited financial results for the quarter ended 31st December 2025 - Trading window…
Kabra Drugs Ltd. Shares Compliance Update for Q4 2025 📄 - Kabra Drugs Ltd. submitted a compliance certificate for the quarter ended December 31, 2025. - Skyline Financial Services Pvt Ltd, the Registrar and Share Transfer Agent, issued the certificate. - Physical share certificates were processed…
Kabra Drugs Expands into Medical Equipment & EV Components 🚀 - Strategic acquisition of Vassmaan Automotive PVT LTD to enter Medical Equipment & EV Components manufacturing. - Expansion of distribution network via agreement with M/s. MR FRANCHISE, adding 200 channel partners nationwide. - Busines…
Kabra Drugs Ltd EGM Results: Key Decisions & Voting Outcomes 📊 - EGM held on 26th December 2025 at Ginger Hotel, Indore - Ms. Ritu Tiwari appointed as Non-Executive Independent Director with 100% votes (2,084,647 votes) - Ms. Nikita Sinha appointed as Non-Executive Independent Director with 100% …
Kabra Drugs Ltd EGM Results: Key Appointments & Approvals 📅 - EGM held on Dec 26, 2025, at Ginger Hotel, Indore, chaired by MD Mr. Nanjappan Aravind. - Remote e-voting took place from Dec 23-25, 2025, scrutinized by M/s. Jay Jain & Associates. - Ms. Ritu Tiwari (DIN: 11040362) appointed as non-ex…
Kabra Drugs Ltd Eyes Expansion & Rebranding 🚀 Key Board Meeting on Jan 1, 2026 - Board meeting set for January 1, 2026, in Chennai. - Proposal to change company name (subject to shareholder & regulatory approval). - Evaluating strategic acquisitions in pharma, medical equipment, EV manufacturing,…
Kabra Drugs Ltd Announces Key Leadership & Policy Updates 🏛️ - EGM scheduled for December 26, 2025, at Ginger Hotel, Indore. - Ms. Ritu Tiwari appointed as Non-Executive Independent Director (Oct 8, 2025 – Oct 7, 2030). - Ms. Nikita Sinha appointed as Non-Executive Independent Director (Oct 8, 20…
Kabra Drugs Ltd Appoints Mrs. Twinkle Agarwal as Secretarial Auditor for 2025-2030 📊 - Mrs. Twinkle Agarwal appointed as Secretarial Auditor for financial years 2025-2026 to 2029-2030. - She is a Practicing Company Secretary (Membership No: 52868, COP No: 25605). - Appointment made during board m…
🔍 Kabra Drugs Ltd’s Secretarial Auditor Resigns – Key Details - Mr. Tanuj Jain Susilkumar (Membership No. 63663, COP No. 23826) resigns as Secretarial Auditor of Kabra Drugs Ltd. - Resignation effective from November 27, 2025. - Covers financial years 2025-2026 to 2029-2030. - Reason cited: 'Othe…
Kabra Drugs Ltd Announces Key Leadership & Expansion Moves 📈 - Ms. Ritu Tiwari and Ms. Nikita Sinha appointed as Non-Executive and Independent Directors. - Agreement approved with M/s. MR FRANCHISE to onboard 200 channel partners nationwide. - Revised remuneration approved for Mr. Kuniamuthur Nan…
Kabra Drugs Expands Nationwide with 200 New Channel Partners 🤝 - Agreement signed with MR FRANCHISE to onboard ~200 channel partners nationwide. - Board meeting scheduled for November 28, 2025, at Corporate Office in Chennai. - Recommendations to appoint Ms. Ritu Tiwari and Ms. Nikita Sinha as Di…
Kabra Drugs Ltd Q2 2025: Revenue Jumps, Profit Swings to Positive 📈 - Total assets as of September 30, 2025: ₹5,450.18 lakhs (current assets: ₹5,319.87 lakhs). - Cash & equivalents dropped to ₹1,160.99 lakhs (from ₹2,129.93 lakhs in March 2025). - Q2 revenue from operations: ₹1,976.40 lakhs (vs. …